Based on this information, the purpose of the study is to examine the correlation between first-line (steroids and IVIg) and second-line (rituximab, TPO-Ras, and immunosuppressive agents) treatments in patients diagnosed with ITP, in terms of (a) platelet count, (b) megakaryocyte morphology, and (c) cure achieved in the 3rd and 12th months of treatment. Here, TPO is linked to autoimmune thrombocytopenic purpura.